Rigvir® is the first oncolytic viral therapy approved for use worldwide. Containing an oncotropic and oncolytic virus type, in clinical trials Rigvir® has shown great efficacy in patients with both early and later stage cancer types. Innovative in design, yet non- genetically modified, Rigvir® contains a live non-pathogenic virus ECHO-7. (Enteric Cytopathic Human Orphan). The mechanism of Rigvir® in the body is highly anticipated by those fighting cancer as there are only short-term mild side effects. This is because unlike traditional chemotherapy treatments, Rigvir® keeps healthy cells intact and simultaneously strengthens the immune system. Rigvir® belongs to the medication group called immunomodulators. Rigvir® is virus based immunomodulator with anti-tumoral response for the treatment of melanoma, local treatment of skin and subcutaneous metastases of melanoma, for prevention of relapse and metastases after radical surgery. Since 2011 Rigvir® is fully reimbursed for residents of Latvia and over 70% of reimbursed melanoma patients have been treated with Rigvir®. Since 2015 Rigvir®is included in the national guidelines for melanoma treatment in Latvia. Both pre-registration and post-registration studies have demonstrated a significant RIGVIR® response to many cancer types besides melanoma.
Oncolytic virus Rigvir® extends progression-free time in stage 2 melanoma patients in a retrospective study. The results show that the patients treated with Rigvir® had 4.39 to 6.57 times lower mortality, that is they were 4-6 times more likely to survive.
Rigvir mode of action
In our practice, besides melanoma Rigvir® has been shown to be especially effective against the following cancer types:
Sarcomas are a relatively rare group of cancers affecting connective tissues of the body such as cartilages, tendons, ligaments, muscle fibers, blood vessels and fat. These cancers tend to be mainly aggressive and in case of progressive disease, conventional systemic treatment shows poor efficacy. The use of Rigvir® has shown promising results, both by extending life and halting further spread of metastases. Novel in its cancer fighting approach, Our clinic offers treatment with this innovative oncolytic virotherapy as part of an approved regimen.
Kidney Cancer comprises of three different types, Renal Cell Carcinoma (RCC) being the most common of them, making up to 85% of all cases. RCC is an immunogenic cancer, meaning that it shows good response to immunotherapies. Risk for kidney cancer is typically associated with abuse of pain medications, smoking, drinking, and genetic predisposition. The use of Rigvir® with immune modulating properties in patients with kidney cancer have shown to be well tolerated and very effective in slowing the growth of cancer throughout the body.
Uterine cancer is the fourth most common cancer for women. Approximately 92% of uterine cancers occur in the endometrium. The five-year survival rate is 81% but lessens significantly with each diagnostic stage. Since the recurrence rate varies and can be a factor, Rigvir® is a promising treatment option. If Uterine Cancer has spread regionally, the survival rate is a moderate 69%. Efforts to halt further metastasis incidence gives further credence to the administration of Rigvir®. With praise from the medical community, Rigvir® has shown to be a viable option with those diagnosed with Uterine Cancer.
The pancreas is actually a gland sandwiched between the spine and stomach.While pancreatic cancer survival rates have been improving from decade to decade, the disease is still considered largely incurable. According to the American Cancer Society, for all stages of pancreatic cancer combined, the one-year relative survival rate is 20%, and the five-year rate is 7%. Special attention has been paid to the notable treatment option, Rigvir® as indicated in a clinical reference on PubMed publication. It is specifically mentioned that pancreas-adenocarcinoma is among the type of cancers that are particularly “sensitive” to the viral properties of Rigvir®. This broadens the perspective of treatment options and why our clinic doesn’t hesitate to recommend the use of this particular oncolytic viral treatment for its patient bodies affected by cancer.
All men are in risk of prostate cancer, therefore prostate cancer is very common in men. In clinical studies of advanced prostate cancer, the use of virotherapy and immunotherapy was clinically proven to assist in long term remission. This is a significant finding given the survival rate for metastasized prostate cancer is indicated to be around only 29%. The GVCC clinic has known Rigvir® to be an option for this and hard to treat cancers therefore adding to the overall treatment regimen to patients. GVCC has known Rigvir® to be a good option for advanced disease in combination with other treatment modalities, nevertheless our clinic promotes Rigvir® in early stage disease, mostly for preventive measures, in order to exclude any potential risk of relapse.
In clinical practice Rigvir® is also applied to fight:
■ Bladder Cancer ■ Colorectal Cancer
■ Stomach Cancer ■ Breast Cancer
■ Lung Cancer ■ Liver Cancer
|Patients involved in melanoma studies||540|
|3-year survival rate (surgery only)||46-58%|
|3-year survival rate (surgery + Rigvir)||57-84%|
|5-year survival rate (surgery + Rigvir)||44-66%|
|3-year survival rate (ocular melanoma)||90%|
|5-year survival rate (ocular melanoma)||70%|
|Patients involved in studies||160|
|5-year survival rate, stage III (post-surgery)||24-33%|
|5-year survival rate, stage III (post-surgery + Rigvir)||47-60%|
|5-year survival rate, stage III (post-surgery)||41-68%|
|5-year survival rate, stage III (post-surgery + Rigvir)||71-78%|